These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34160460)

  • 41. Long-Term Changes in the Treatment Pattern of Botulinum Toxin A Injections for Postfacial Paralysis Synkinesis Following Modified Selective Neurectomy.
    Hjelm N; Crippen M; Azizzadeh B
    Facial Plast Surg Aesthet Med; 2021; 23(3):234-235. PubMed ID: 33306003
    [No Abstract]   [Full Text] [Related]  

  • 42. Quantitative changes in botulinum toxin a treatment over time in patients with essential blepharospasm and idiopathic hemifacial spasm.
    Snir M; Weinberger D; Bourla D; Kristal-Shalit O; Dotan G; Axer-Siegel R
    Am J Ophthalmol; 2003 Jul; 136(1):99-105. PubMed ID: 12834676
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Therapeutic Approach to Botulinum Injections for Hemifacial Spasm, Synkinesis and Blepharospasm.
    Yahalom G; Janah A; Rajz G; Eichel R
    Toxins (Basel); 2022 May; 14(5):. PubMed ID: 35622608
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term Efficacy of Botulinum Neurotoxin-A Treatment for Essential Blepharospasm.
    Lee S; Park S; Lew H
    Korean J Ophthalmol; 2018 Feb; 32(1):1-7. PubMed ID: 29376224
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Experience with long-term treatment with albumin-supplemented botulinum toxin type A.
    Mohammadi B; Kollewe K; Wegener M; Bigalke H; Dengler R
    J Neural Transm (Vienna); 2009 Apr; 116(4):437-41. PubMed ID: 19319477
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of blepharospasm with botulinum neurotoxin type A: long-term results.
    Calace P; Cortese G; Piscopo R; Della Volpe G; Gagliardi V; Magli A; De Berardinis T
    Eur J Ophthalmol; 2003 May; 13(4):331-6. PubMed ID: 12872788
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Safety and efficacy of botulinum toxin in hemifacial spasm].
    Mazlout H; Kamoun Gargouri H; Triki W; Kéfi S; Brour J; El Afrit MA; Chéour M; Kraiem A
    J Fr Ophtalmol; 2013 Mar; 36(3):242-6. PubMed ID: 23270989
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Five-Year Retrospective Review of Cases with Benign Essential Blepharospasm and Hemifacial Spasm Presenting in a Tertiary Eye Care Center in North India.
    Raj A; Arya SK; Deswal J; Bamotra RK
    Semin Ophthalmol; 2017; 32(3):371-376. PubMed ID: 27078720
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Retrospective evaluation of the dose equivalence of Botox(®) and Dysport (®) in the management of blepharospasm and hemifacial spasm: a novel paradigm for a never ending story.
    Bentivoglio AR; Ialongo T; Bove F; De Nigris F; Fasano A
    Neurol Sci; 2012 Apr; 33(2):261-7. PubMed ID: 21710123
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of aberrant facial nerve regeneration with botulinum toxin A.
    Chua CN; Quhill F; Jones E; Voon LW; Ahad M; Rowson N
    Orbit; 2004 Dec; 23(4):213-8. PubMed ID: 15590522
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Buccinator synkinesis treated by botulinum toxin in facial palsy and hemifacial spasms.
    Kanerva M
    J Plast Reconstr Aesthet Surg; 2021 Jul; 74(7):1464-1469. PubMed ID: 33358465
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].
    Wissel J; Entner T
    Wien Klin Wochenschr; 2001; 113 Suppl 4():20-4. PubMed ID: 15506048
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Five-Year Prospective Study of Quality of Life in Hemifacial Spasm Treated with Abo-Botulinum Toxin A.
    Kongsaengdao S; Maneeton N; Maneeton B
    Toxins (Basel); 2021 Mar; 13(3):. PubMed ID: 33809486
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Botulinum toxin type A for facial rejuvenation. United States and United Kingdom perspectives.
    Lowe NJ
    Dermatol Surg; 1998 Nov; 24(11):1216-8. PubMed ID: 9834741
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prospective, randomized, double-blind study, comparing botulinum toxins type a botox and prosigne for blepharospasm and hemifacial spasm treatment.
    Quagliato EM; Carelli EF; Viana MA
    Clin Neuropharmacol; 2010; 33(1):27-31. PubMed ID: 20124784
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of Safety and Efficacy of Botox and Neuronox in the Management of Benign Essential Blepharospasm: A Split-face Study.
    Sane S; Ali MJ; Naik MN
    Korean J Ophthalmol; 2019 Oct; 33(5):430-435. PubMed ID: 31612653
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Essential blepharospasm and hemifacial spasm: characteristic of the patient, botulinum toxin A treatment and literature review].
    Schellini SA; Matai O; Igami TZ; Padovani CR; Padovani CP
    Arq Bras Oftalmol; 2006; 69(1):23-6. PubMed ID: 16491229
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The role of the injection botulinum toxin A in cases of blepharospasm syndrome, hemifacial spasm and Meige's syndrome.
    Bastola P; Chaudhary M; Agrawal JP; Shah DN
    Kathmandu Univ Med J (KUMJ); 2010; 8(31):305-10. PubMed ID: 22610735
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Increasing the area and varying the dosage of Botulinum toxin a injections for effective treatment of hemifacial spasm.
    Choe WJ; Kim J
    Acta Otolaryngol; 2016 Sep; 136(9):952-5. PubMed ID: 27067535
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Riolan's muscle: action and indications for botulinum toxin injection.
    Mackie IA
    Eye (Lond); 2000 Jun; 14 ( Pt 3A)():347-52. PubMed ID: 11026998
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.